Ciprofloxacin for post-exposure prophylaxis of anthrax : emergency use instructions for healthcare providers

Details

• Alternative Title:
  Ciprofloxacin EUI for Healthcare Providers ; Ciprofloxacin Emergncy Use Instructions for Healthcare Providers
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  This fact sheet provides instructions for the use of ciprofloxacin for post‐exposure prophylaxis (PEP) during an emergency involving anthrax (referred to as Emergency Use Instructions (EUI) fact sheet). Ciprofloxacin is FDA‐approved for PEP of inhalation anthrax – to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis (B. anthracis). The Food and Drug Administration (FDA) has also issued an order permitting the emergency dispensing of oral formulations of ciprofloxacin without a prescription during an anthrax emergency to individuals who may have been exposed to B. anthracis.
  
  Ciprofloxacin EUI for Healthcare Providers (originally issued 03/28/2016; revised 08/18/2017)
  
  cipro-eui-hcp-H.pdf
  
  
• Subjects:
  Anthrax Ciprofloxacin Emergencies Post-Exposure Prophylaxis
• Document Type:
  Pamphlet (or booklet)
• Genre:
  Guidance
• Pages in Document:
  2 numbered pages
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:c8b80577e837e7c7846a4d2ff963c6c28370494de82fd3d2580e14ad35c47275
• Download URL:
  https://stacks.cdc.gov/view/cdc/56838/cdc_56838_DS1.pdf
• File Type:
  [PDF - 183.85 KB ]